My watch list
my.bionity.com  
Login  

Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.

28-Apr-2009

VaxOnco Inc, a Korean company specializing in peptide based vaccines, has acquired Pharmexa-Epimmune (Pharmexa Inc.) by the purchase of all outstanding shares from Pharmexa A/S for €440,000. VaxOnco will thus assume all rights and responsibilities relating to the Pharmexa-Epimmune patent portfolio.

Dr. Achim Kaufhold, Pharmexa´s CEO, says “In line with our cost-cutting activities and our new strategic direction, Pharmexa A/S discontinued operations at our Pharmexa-Epimmune subsidiary in San Diego at the end of last year. The sale of Pharmexa-Epimmune to VaxOnco completes that process and will result in substantial savings to Pharmexa A/S in the future.”

Facts, background information, dossiers
More about Pharmexa
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE